Quanterix Simoa® Technology Powers Breakthrough Alzheimer’s Disease Research Presented by Eli Lilly and Company at Alzheimer’s Association International Conference (AAIC) 2021

By | August 9, 2021
Ultra-sensitive Simoa® HD-X technology powers new findings that detect rapid reduction of plasma P-tau217 from donanemab, Lilly’s investigational antibody therapy for Alzheimer’s disease at 12 weeks